(Q40914660)

English

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 September 2017

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial (English)

1 reference

Europe PubMed Central

24 September 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Carsten Denkert

6

1 reference

Europe PubMed Central

24 September 2017

Silvia Darb-Esfahani

18

object named as

Silvia Darb-Esfahani

0 references

Wolfgang D Schmitt

object named as

Wolfgang Daniel Schmitt

19

0 references

Andreas Schneeweiss

3

object named as

Andreas Schneeweiss

1 reference

Europe PubMed Central

24 September 2017

24

object named as

Sibylle Loibl

1 reference

Europe PubMed Central

24 September 2017

1

object named as

Michael Untch

1 reference

Europe PubMed Central

24 September 2017

5

object named as

Bahriye Aktas

1 reference

Europe PubMed Central

24 September 2017

author name string

Christian Jackisch

2

1 reference

Europe PubMed Central

24 September 2017

Bettina Conrad

4

1 reference

Europe PubMed Central

24 September 2017

Holger Eidtmann

7

1 reference

Europe PubMed Central

24 September 2017

Hermann Wiebringhaus

8

1 reference

Europe PubMed Central

24 September 2017

Sherko Kümmel

9

1 reference

Europe PubMed Central

24 September 2017

Jörn Hilfrich

10

1 reference

Europe PubMed Central

24 September 2017

Mathias Warm

11

1 reference

Europe PubMed Central

24 September 2017

Stefan Paepke

12

1 reference

Europe PubMed Central

24 September 2017

Marianne Just

13

1 reference

Europe PubMed Central

24 September 2017

Claus Hanusch

14

1 reference

Europe PubMed Central

24 September 2017

John Hackmann

15

1 reference

Europe PubMed Central

24 September 2017

Jens-Uwe Blohmer

16

1 reference

Europe PubMed Central

24 September 2017

Michael Clemens

17

1 reference

Europe PubMed Central

24 September 2017

Serban Dan Costa

20

1 reference

Europe PubMed Central

24 September 2017

Bernd Gerber

21

1 reference

Europe PubMed Central

24 September 2017

Knut Engels

22

1 reference

Europe PubMed Central

24 September 2017

Valentina Nekljudova

23

1 reference

Europe PubMed Central

24 September 2017

Gunter von Minckwitz

25

1 reference

Europe PubMed Central

24 September 2017

German Breast Group (GBG)

26

1 reference

Europe PubMed Central

24 September 2017

Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) Investigators

27

1 reference

Europe PubMed Central

24 September 2017

publication date

8 February 2016

1 reference

Europe PubMed Central

24 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

24 September 2017

17

1 reference

Europe PubMed Central

24 September 2017

3

1 reference

Europe PubMed Central

24 September 2017

345-356

1 reference

Europe PubMed Central

24 September 2017

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant docetaxel for high-risk, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly paclitaxel in the adjuvant treatment of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Albumin-bound paclitaxel: a next-generation taxane

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900542-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00542-2

1 reference

Europe PubMed Central

24 September 2017

1 reference

Europe PubMed Central

24 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40914660&oldid=2092552548"